DLX4 and breast neoplasm: Overall, BP1 mRNA expression was found in 80% of breast tumors, with an 11% rate of low BP1 mRNA in normal tissues, while 100% of ER-negative tumors expressed BP1. These data suggest BP1 might be a useful target for therapy in patients with ER-negative tumors.